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Abstract 
Background and objectives: In this study, our goal was to compare intraoperative and postoperative 
analgesic effects of lornoxicam and fentanyl when added to lidocaine Intravenous Regional 
Anesthesia (IVRA) in a group of outpatients who underwent hand surgery. 
Methods: This is a double blind randomized study. A total of 45 patients were included, randomized 
into three groups. Patients in Group I (L) received 3 mg.kg-1 of 2% lidocaine 40 mL; patients in 
Group II (LL) received 3 mg.kg-1 lidocaine 38 mL + 2 mL lornoxicam; patients in Group III (LF) 
received 3 mg.kg-1 lidocaine 38 mL + 2 mL fentanyl. Our primary outcome was ﬁ rst analgesic 
requirement time at postoperative period. 
Results: Lornoxicam added to lidocaine IVRA increased the sensory block recovery time without 
increasing side effects and increased ﬁ rst analgesic requirement time at the postoperative 
period when compared to lidocaine IVRA (p < 0.001, p < 0.001 respectively) and fentanyl added 
to lidocaine IVRA (p < 0.001, p < 0.001 respectively). In addition, we also found that fentanyl 
decreased tourniquet pain (p < 0.01) when compared to lidocaine but showed similar analgesic 
effect with lornoxicam (p > 0.05) although VAS scores related to tourniquet pain were lower 
in fentanyl group. Lornoxicam added to lidocaine IVRA was not superior to lidocaine IVRA in 
decreasing tourniquet pain.
Conclusions: Addition of fentanyl to lidocaine IVRA seems to be superior to lidocaine IVRA 
and lornoxicam added to lidocaine IVRA groups in decreasing tourniquet pain at the expense 
of increasing side effects. However, lornoxicam did not increase side effects while providing 
intraoperative and postoperative analgesia. Therefore, lornoxicam could be more appropriate 
for clinical use.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
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Introduction
Intravenous regional anesthesia (IVRA) is a safe and fair 
efﬁ cient method that is easy to perform in outpatient 
extremity surgery lasting less than one hour 1. The success 
rate of IVRA is approximately 95-100%. The advantage of 
this method is fast return of the extremity motor function 
and sensation feeling to normal functioning at the end 
of the surgery. Such quick recovery enables patients to 
be discharged earlier 1,2. However, this method has also 
disadvantages such as tourniquet pain, insufﬁ cient muscle 
relaxation, insufﬁ cient postoperative analgesia and local 
anesthetic toxicity 3. 
In order to prevent disadvantages with IVRA, many ad-
juvant drugs have been added to local anesthetics to obtain 
better intraoperative anesthesia, to prevent tourniquet pain 
and to prolong postoperative analgesia 4-8. In many studies 
in the literature, IVRA has been combined with adjunctive 
drugs such as ketorolac 4, NSAIDs 5,7, paracetamol 6, ket-
amine 8, opioids 9 and α-2 adrenergic receptor agonists 10. 
Various NSAID studies have demonstrated successful im-
provement in analgesia when added to lidocaine in IVRA. 
Opioid studies (on morphine and tramadol) have shown 
that the addition of opioids to IVRA improves postoperative 
analgesia compared with placebo adjuvant. On the other 
hand, the combination of lidocaine IVRA with morphine or 
tramadol has been reported to improve postoperative anal-
gesia and sensory block, albeit not providing any advantages 
on tourniquet pain, motor block quality, analgesia duration 
or analgesic consumption 9.
There are no clinical studies in the literature to the best 
of our knowledge comparing the efﬁ cacy of lornoxicam and 
fentanyl when added to lidocaine IVRA, or efﬁ cacy of opioid 
drug fentanyl as an adjuvant added to lidocaine IVRA. 
In our current study, we hypothesized that fentanyl 
should have a more favorable effect in minimizing intra-
operative tourniquet pain than lornoxicam. However, due 
to long half-life lornoxicam could have a longer analgesic 
effect at the postoperative period when compared to fen-
tanyl. Our primary outcome was ﬁ rst analgesic requirement 
time. Our secondary outcomes were tourniquet pain and 
sensory block recovery time at postoperative period.
Method
The local ethics committee of Ege University Hospital ap-
proved this double blind randomized study. We informed 
all patients about the study protocol and obtained written 
informed consent. 
Patients who were between the ages of 18 and 60, whose 
ASA physical states were I-II, who were scheduled to undergo 
outpatient hand surgery due to carpal tunnel syndrome, 
Dupuytren’s contracture, trigger ﬁ nger and ganglion cyst 
were recruited for the current study. We excluded from 
the study the patients who had uncontrolled hypertension, 
epilepsy, diabetic neuropathy, Reynaud’s disease, drug and 
local analgesic allergies or opioid addiction. The study began 
January 2010 and ended May 2010 and, in this time frame, 
a total of 45 patients were included. 
We monitored heart rate (HR), mean arterial pressure 
(MAP) and peripheral oxygen saturation (SpO2) of patients in 
the operating room (Hewlett Packard -Viridia 24C France). 
We attached a double-cuff tourniquet to the arm to be 
operated. In order to inject local anesthetic on the arms 
that would be operated, a 24G cannula was inserted in a vein 
on the dorsal hand. Another IV, 20G cannula was prepared 
for ﬂ uid infusion on the other hand.
In the operative upper extremity, we drained the veins 
by lifting them up for 3 minutes and tightly wrapping the 
arm with Esmarch bandage until the distal cuff of the tour-
niquet. Afterwards, we inﬂ ated a double-cuff pneumatic 
tourniquet (VBM Medizintechnik GmbH Germany) until the 
proximal cuff pressure was at least 100 mmHg more than 
the systolic arterial pressure (minimum 250 mm Hg). Then 
the Esmarch bandage was removed. As a result we observed 
loss of radial pulse, trace loss in the pulse oximetry and 
absence of circulation in the arm. Then, we injected a local 
anesthetic and adjuvant mixture through the vascular access 
at the operative extremity. A physician who was blinded 
to the randomization scheme provided intraoperative and 
postoperative evaluations.
Patients were randomized into three groups based 
on a computer generated, random number sequence and 
sealed envelopes. Patients in Group I (L) received 3 mg.
kg-1 lidocaine 40 mL (2% Lidocaine, Aritmal, Biosel, Turkey); 
patients in Group II (LL) received 3 mg.kg-1 lidocaine 38 
mL + 2 mL lornoxicam (4 mg.mL-1 Lornoxicam, Xefo, Abdi 
Ibrahim, Turkey); patients in Group III (LF) received 3 mg.
kg-1 lidocaine 38 mL + 2 mL fentanyl (0.05 mg.mL-1 Fentanyl 
citrate, Hospira, USA). The local anesthetic with adjuvant 
drug mixture was administered via slow IV infusion over 2 
minutes to the extremity with no circulation. The distal 
cuff on the upper arm was inﬂ ated 10 minutes after the 
administration of the drug, then, the proximal cuff was 
deﬂ ated.
We evaluated patients’ motor and sensory block as fol-
lows: motor block in ﬁ nger and wrist movements as: 0 = 
no motor impairment, 1 = partial power loss, 2 = complete 
power loss ; sensory block was evaluated with the pinprick 
test performed every minute using a 22G needle on the 
radial, median, ulnar, lateral and medial antebrachial 
cutaneous nerves. 
We recorded times as follows 11:
Motor block onset time: Time elapsed from the 
injection of the drug until 
complete power loss in hand 
and wrist was established
Sensory block onset time: Time elapsed from the 
injection of the drug until 
complete sensory block 
was established in all 
dermatomes
Motor block recovery 
time:
Time elapsed from the 
removal of the tourniquet 
to the initiation of motor 
movement in hand and wrist
Sensory block recovery 
time:
Time elapsed from the 
removal of the distal 
tourniquet until the 
disappearance of complete 
sensory block in all 
dermatomes
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Analgesia duration: Time elapsed from the 
opening of the tourniquet 
until the start of the initial 
pain
VAS scores at 5, 10, 15, 20, 25, and 30 minutes were 
evaluated and recorded after the proximal tourniquet on 
the upper arm was deﬂ ated and distal tourniquet was in-
ﬂ ated. For those who had VAS above 4, a total of 1 μg.kg-1 
IV fentanyl was administered. In patients who continued to 
have pain despite this, general anesthesia with a laryngeal 
mask was used and recorded. Intraoperative hypotension 
(25% lower than basal) was treated with 5 mg IV ephed-
rine, bradycardia (25% of basal) was treated with 0.5 mg IV 
atropine. The patients who had nausea and vomiting were 
treated with 4 mg IV ondansetron. Those with 95% oxygen 
saturation were given 5 L.min-1 oxygen supports via mask 
and recorded. Patient satisfaction was evaluated at the end 
of the operation as follows 11: 
4- Excellent: No complaint from the patient
3- Good: Minor complaint with no need for supplemental 
analgesics
2- Moderate: Complaint, which required supplemental 
analgesic (fentanyl IV 1 μg.kg-1).
1- Unsuccessful:  Patient transitioned to general 
anesthesia. 
Tourniquet pressure was released with several minute 
intervals and at least 30 minutes after the drug injection.
We recorded postoperative pain scores (VAS) at 30 min-
utes, and 1, 2, 4, 6, and 24 hours. MAP, HR and sedation 
scores were also recorded at same time points. Those with 
VAS > 4 were given IV paracetamol. Patient who continued 
to have pain after paracetamol, were given 50 mg IV mep-
eridine. In addition, we observed local anesthetic toxicity 
and postoperative opioid drug side effects such as nausea, 
vomiting, skin rash, tinnitus, convulsion in patients. Then, 
we conducted a 24th hour postoperative check up by calling 
the patients at home and recording results.
In the current study, our primary outcome was ﬁ rst anal-
gesic requirement time. Sample size calculation was based 
on ﬁ rst analgesic requirement time. Therefore, to reach 
statistically signiﬁ cant difference between three groups 
a sample size was calculated by accepting an alpha risk 
of 5% and a power (1-β) of 99%. From this calculation, 15 
subjects in each group would be necessary for a signiﬁ cant 
difference (p < 0.05). Statistical analysis was conducted 
using computer software package SPSS 16.0 (SPSS Inc., 
Chicago, Illinois). We summarized data as mean ± standard 
deviation. In order to analyze differences between groups 
based on numeric variables that show normal distribution, 
we used the ANOVA test and then Bonferroni’s correction. 
For repeated measurements, we used a variance analysis. 
In comparison of categorical data groups, cross tables 
were formed and Chi-Square test was used. In the analysis 
of variables not showing normal distribution we used the 
Kruskal Wallis and the Mann-Whitney U tests. In all tests, p 
value < 0.05 was considered statistically signiﬁ cant.
Results
Table 1 shows patients’ demographic and perioperative 
data, onset and recovery times of sensory and motor blocks. 
Demographical characteristics of the patients in three 
groups did not show statistically signiﬁ cant difference. In 
addition, three groups did not show any signiﬁ cant differ-
ence in terms of operation and tourniquet times (p > 0.05, 
Table 1).
Motor and sensory block onset times, motor block recov-
ery time and degree of motor block were similar between 
three groups, but the difference in terms of sensory block 
recovery time and ﬁ rst analgesic requirement time were 
statistically signiﬁ cant between three groups (Table 1). The 
difference was due to the comparison of Group I and Group II 
(for sensory block recovery time p < 0.001; for ﬁ rst analgesic 
requiring time p < 0.001) and Group II and Group III (for 
sensory block recovery time p < 0.001; for ﬁ rst analgesic 
requiring time p < 0.001). Group II had both longer sensory 
block recovery time and ﬁ rst analgesic requirement time 
than the other two groups. No signiﬁ cant difference was 
Table 1 - Demographic and Perioperative Data and Onset and Recovery Times of Sensory and Motor Blocks.
GROUP I GROUP II GROUP III p
Age (year) 50 ± 12 50 ± 10 48 ± 16 0.846
Height (cm) 166 ± 6 165 ± 8 164 ± 9 0.765
Weight (kg) 78 ± 14 75 ± 11 74 ± 18 0.761
ASA( I/II) 7/8 7/8 6/9 0.914*
Operation Time ( min) 23 ± 3 22 ± 2 22 ± 2 0.765
Turniquet Time (min) 30 ± 3 29 ± 3 29 ± 3 0.859
Motor block onset time (min) 9.0 ± 1.81 8.93 ± 1.62 8.73 ± 1.58 0.902
Sensory block onset time (min) 6.53 ± 1.68 6.73 ± 1.58 6.73 ± 1.49 0.924
Sensory block recovery time (min) 21.0 ± 5.41 30.7 ± 3.37 23.67 ± 4.22 p < 0.001
Motor block recovery time (min) 6.0 ± 1.13 5.73 ± 1.16 6.13 ± 1.36 0.66
First analgesia requiring time (min) 26.3 ± 7.7 41 ± 6.04 27.7 ± 5.6 p < 0.001
Intraoperative analgesia need (# patients) 3 2 0 0.34*
Three groups compared with ANOVA; *Chi square and Fisher’s Exact tests results.
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obtained in terms of sensory block recovery time and ﬁ rst 
analgesic requirement time from the comparison of Group 
I and Group III (Table 1).
Comparison of intraoperative tourniquet VAS scores 
revealed signiﬁ cant differences between three groups 
(Figure 1). Pairwise comparisons revealed that the differ-
ence was due to comparison of Group I and Group III. No 
signiﬁ cant differences were observed in terms of VAS scores 
at each time interval from the comparisons of Group I and 
Group II and Group II and Group III (Table 2). 
Regarding postoperative VAS scores, the scores at 30 
minutes and 4 hours after operation were signiﬁ cantly 
different between three groups (p = 0.004 and p = 0.01 
respectively, Figure 2). For both time intervals, the differ-
ence was due to the comparison of Group I versus Group 
II and Group I versus Group III (Table 2). No statistically 
signiﬁ cant difference was found between group II and Group 
III in terms of VAS scores at 30 minutes and at 4 hours 
postoperatively. 
Table 2 - Pairwise Comparisons of Intraoperative and Postoperative VAS Scores.
Time intervals Group I vs Group II Group I vs Group III Group II vs Group III
TPVAS 5 (min) p = 0.2 p = 0.002* p = 0.07
TPVAS 10 (min) p = 0.19 p = 0.002* p = 0.069
TPVAS 15 (min) p = 0.06 p = 0.001* p = 0.12
TPVAS 20 (min) p = 0.09 p = 0.005* p = 0.18
TPVAS 25 (min) p = 0.05 p = 0.003* p = 0.28
TPVAS 30 (min) p = 0.09 p = 0.003* p = 0.19
TRVAS 30 (min)* p = 0.002 p = 0.008 p = 0.61
TRVAS 1 (hour) p = 0.23 p = 0.44 p = 0.73
TRVAS 2 (hour) p = 0.18 p = 0.13 p = 0.93
TRVAS 3 (hour) p = 0.53 p = 0.27 p = 0.83
TRVAS 4 (hour)* p = 0.005 p = 0.01 p = 0.78
TRVAS 6 (hour) p = 1.0 p = 1.0 p = 1.0
TRVAS 24 (hour) p = 1.0 p = 1.0 p = 1.0
Mann-Whitney U test result, *p < 0.05. TPVAS: tourniquet pain VAS (intraoperative), TRVAS: tourniquet release VAS 
(postoperative).
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Figure 1 Intraoperative (tourniquet pain) VAS. Figure 2 Postoperative VAS.
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There was no statistically signiﬁ cant difference in the 
MAP, HR values between the three groups at any time during 
the study (p > 0.05).
When the groups were analyzed based on intraopera-
tive and postoperative side effects, there was one case of 
local anesthetic systemic toxic reaction with tinnitus and 
nearly fainting as symptoms in each group. In Group III, 
we observed opioid side effects such as nausea, vomiting 
and itching (Table 3). Hemodynamic instability was not 
observed in any of the patients. In regards to the need 
for postoperative additional analgesia (rescue analgesia), 
no significant difference was observed between groups 
(p = 0.2, Table 3).
Discussion
The main ﬁ ndings of our study were: addition of NSAID 
lornoxicam to lidocaine IVRA increased the sensory 
block recovery time without increasing side effects and 
increased ﬁ rst analgesic requirement time compared to 
lidocaine IVRA as well as fentanyl added to lidocaine IVRA. 
In addition, we found that fentanyl added to lidocaine IVRA 
showed better intra-operative analgesic effect (decreased 
tourniquet pain) than lidocaine IVRA but showed similar 
analgesic effect when compared to lornoxicam added to 
lidocaine IVRA. However, lornoxicam added to lidocaine 
IVRA was not superior to lidocaine IVRA in decreasing 
tourniquet pain. 
Intravenous lidocaine interacts with peripheral and 
central voltage-gated Na+ channels, in the intracellular 
side of the cell membrane. Intravenous lidocaine affects 
peripheral and central nerve endings. Data in the literature 
indicate that central sensitization resulting from tissue dam-
age would be minimized by lidocaine in different levels of 
the nervous system depending on the damage. Intravenous 
lidocaine administration increases the acetylcholine (Ach) 
concentration in the cerebrospinal ﬂ uid and analgesic effect 
of lidocaine is thought to be the result of binding Ach to 
muscarinic M3 receptors, by inhibition of glycine receptors 
and by releasing endogenous opioids, which would exacer-
bate the inhibitory descending pain pathways resulting in 
analgesia.  Intravenous lidocaine reduces the inﬂ ammatory 
response to tissue ischemia and attenuates the tissue dam-
age induced by endothelial and vascular cytokines through a 
mechanism involving the release of adenosine triphosphate 
and K+ channels 12.
In the current study we found that lornoxicam added 
to lidocaine IVRA improved sensory block and postopera-
tive analgesia compared to lidocaine IVRA and fentanyl 
added to lidocaine IVRA. This ﬁ nding was in line with 
the prior lornoxicam study ﬁ ndings and the NSAID study 
ﬁ ndings 5,7.
Lornoxicam is a NSAID from the oxicam category that 
has analgesic and anti-inﬂ ammatory effects. Lornoxicam 
blocks cyclooxygenase-2 enzyme (COX-2) which inhibits 
prostaglandins that are responsible for recognition and 
transduction of pain stimulation. The inhibition of pros-
taglandin synthesis by NSAIDs has been demonstrated to 
effectively reduce inﬂ ammatory symptoms such as edema 
and pain. COX-2 is an inducible molecule that takes several 
hours to induce inﬂ ammatory pain. Therefore only COX-2 
inhibition properties of lornoxicam do not explain its an-
algesic effects. Other mediators of inﬂ ammation such as 
reactive oxygen products and cytokines have also been 
shown to contribute to inﬂ ammation and inﬂ ammatory 
pain. By induction of COX-2 gene nitric oxide synthase is 
induced and it leads to increased levels of nitric oxide in 
inﬂ amed tissues.  Nitric oxide has been shown to contrib-
ute to edema formation, hyperalgesia and pain. Another 
important element of the pro-inﬂ ammatory process is 
the presence of cytokines such as tumor necrosis factor 
(TNF)-α, interleukin (IL)-1β, IL-6 and IL-8. Berg et al. in-
vestigated the effect of lornoxicam on human COX-1 and 
human COX-2, on nitric oxide synthase and on the formation 
of TNF-α, IL-1β, IL-6, and IL-8 and they found that lornoxi-
cam inhibited COX-isoenzymes equipotently and inhibited 
IL-6 and nitric oxide production, thus all these effects 
of lornoxicam are the result of its anti-inflammatory 
Table 3 - Complications and Patients’ Satisfaction from the Procedure.
Group I Group II Group III P
Nausea 0 0 2 0.12
Vomiting 0 0 1 0.36
Tinnitus 1 1 1 -
Itching 0 0 3  0.04*
Convulsion 0 0 0 -
Rescue analgesia 3 2 0 0.21
Patient satisfaction (1/2/3/4) 2/2/5/6 0/1/4/10 0/2/5/8 0.47
Chi square and Fisher’s Exact tests results. *p < 0.05.
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and analgesic effect 13. In the current study, we did not 
observe short-term analgesic effects of lornoxicam. Thus 
lornoxicam did not provide good quality of analgesia in 
terms of tourniquet pain. Therefore, this ﬁ nding was not 
comparable with the ﬁ ndings emphasizing the advantages 
of lornoxicam on tourniquet pain 14. Lornoxicam is rapidly 
eliminated, having a plasma elimination half-life of 3-5 
hours 13. In our study, favorable analgesic effect of lor-
noxicam was limited to four hours as shown by postopera-
tive VAS scores, which were congruent with lornoxicam’s 
elimination half-life.
Our study also evaluated the intraoperative and 
postoperative analgesic effects of fentanyl when added 
to lidocaine IVRA. Opioids have central effects and are 
synthesized especially after tissue damage as a result of 
activated opioid receptors. Due to these peripheral ef-
fects, using opioids combined with local anesthetics have 
increased in regional anesthesia applications 15. The results 
of the studies concerning the analgesic effects of opioids 
(morphine and tramadol) are scarce and, based on the 
studies regarding the addition of morphine to the local 
anesthetic in IVRA, we did not ﬁ nd that increasing the dose 
of morphine increased intraoperative and postoperative 
analgesic effect 9,15,16.
Our study is the ﬁ rst that observed analgesic effects 
of fentanyl in IVRA. Although fentanyl is a more potent 
analgesic than lornoxicam, we could not show advantages 
of fentanyl on tourniquet pain as compared to lornoxicam 
in current study. This could be due to the small sample 
size. In addition, we did not show superiority of fentanyl in 
terms of postoperative analgesic need when compared to 
lornoxicam added to lidocaine IVRA and to lidocaine IVRA. 
This may be due to fentanyl’s short half-life. 
After the tourniquet deﬂ ation, local anesthetic toxicity 
risk increases due to the rapid diffusion of large amounts 
of the local anesthetic into the circulation. For this rea-
son, the local anesthetic amounts used should be limited 
to minimal effective dose to provide surgical anesthesia. 
This, in turn, increases the need for additional analgesics. 
We have achieved adequate anesthesia and analgesia by 
adding lornoxicam and fentanyl. However, further studies 
are needed if lower dose of local anesthetic combinations 
may also provide similar anesthesia quality. 
There are some limitations to our current study. The drug 
doses selected were chosen from the literature. Lornoxicam 
and fentanyl doses were chosen from previous studies. 
Although a higher dose of fentanyl and lornoxicam might 
provide better intraoperative and postoperative analgesia, 
more side effects could be observed. Another limitation is 
small sample size, which may decrease the generality of 
our results.
In conclusion, when fentanyl is added to lidocaine, 
intraoperative tourniquet pain is decreased in expense of 
opioid-related side effects. However, lornoxicam does not 
increase side effects while providing additional intraopera-
tive and postoperative analgesia. Therefore, lornoxicam 
can be accepted as a better adjunctive drug than fentanyl 
in IVRA. 
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